<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04222348</url>
  </required_header>
  <id_info>
    <org_study_id>FIM-MET-2015-01</org_study_id>
    <nct_id>NCT04222348</nct_id>
  </id_info>
  <brief_title>MeDiGes Study: Metformine Use in Gestational Diabetes</brief_title>
  <acronym>FIMMET201501</acronym>
  <official_title>Efficacy of Metformin Treatment in Not Controlled With Diet Gestational Diabetes Versus Use of Insulin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women with gestational diabete (GD) who do not meet glycemic control objectives with diet
      will be assigned to two treatment groups randomly. One: metformin at a dose of 850-2550mg
      every 24h; two: insulin detemir associated or not with rapid insulin analogue (aspart)
      according to your glycemic controls. The Metformin group may additionally receive insulin in
      a second time in case the glycemic control is not appropriate with monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women with gestational diabete (GD) who do not meet glycemic control objectives with diet
      will be assigned to two treatment groups randomly. One: metformin at a dose of 850-2550mg
      every 24h; two: insulin detemir associated or not with rapid insulin analogue (aspart)
      according to your glycemic controls. The Metformin group may additionally receive insulin in
      a second time in case the glycemic control is not appropriate with monotherapy.

      The objectives are: Demonstrate that treatment with metformin in women with GD (not
      controlled with diet) can get no lower obstetric and perinatal outcomes than those with
      standard treatment with insulin.

      Demonstrate that glycemic control with metformin in properly selected women, can be
      equivalent to that obtained with insulin.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 26, 2016</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 28, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Inferiority, randomized, open, parallel arms, multicenter clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metformin benefits</measure>
    <time_frame>50 weeks</time_frame>
    <description>Change of Weigth</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Good glycemic control</measure>
    <time_frame>50 weeks</time_frame>
    <description>Change of glycemic levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baby wellness</measure>
    <time_frame>Delivery</time_frame>
    <description>Weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event profile</measure>
    <time_frame>50 weeks</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fructosamine as a marker of insulinization</measure>
    <time_frame>50 weeks</time_frame>
    <description>Concentration of fructosamine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with the treatment</measure>
    <time_frame>50 weeks</time_frame>
    <description>Questionnaire of satisfaction with the treatment. Range: 5 (worst)-16 (best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 profile</measure>
    <time_frame>50 weeks</time_frame>
    <description>IL-6 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-10 profile and oxidativge stress as well as in lipid profile</measure>
    <time_frame>50 weeks</time_frame>
    <description>IL-10 (ultrasensitive PCR) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin profile</measure>
    <time_frame>50 weeks</time_frame>
    <description>Leptin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ladiponectin and oxidativge stress as well as in lipid profile</measure>
    <time_frame>50 weeks</time_frame>
    <description>Ladiponectin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LPS profile</measure>
    <time_frame>50 weeks</time_frame>
    <description>LPS levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LBP profile and oxidativge stress as well as in lipid profile</measure>
    <time_frame>50 weeks</time_frame>
    <description>LBP levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Diabetes, Gestational</condition>
  <condition>Perinatal Disorder</condition>
  <condition>Puerperal Disorder</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>850-2550 mg every 24h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Detemir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individual doses according to glycemic controls.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>850-2550 mg every 24h.</description>
    <arm_group_label>Insulin Detemir</arm_group_label>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Detemir</intervention_name>
    <description>Insulin detemir associated or not with rapid insulin analogue (aspart) according to individual glycemic controls.</description>
    <arm_group_label>Insulin Detemir</arm_group_label>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-45 years old.

          2. Diagnosis of GD, with fasting glucose &lt;120 mg / dL.

          3. not controlled by diet: fasting capillary blood glucose&gt; 95 mg / dl in at least 2-3
             times or 1 hour postprandial &gt;140 mg / dl on, at least 2-3 times a week.

          4. 2nd or 3rd trimesters of pregnancy.

          5. Able to give informed consent.

        Exclusion Criteria:

          1. Psychopathological situations that do not guarantee proper adhesion to follow up

          2. 1st trimester of pregnancy

          3. gastrointestinal diseases that may cause poorer tolerance or increased symptoms with
             metformin.

          4. Patients who can not attend the scheduled consultation.

          5. Language barrier limiting for understanding treatment settings

          6. Twin pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Puerperal Disorders</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

